Kinnate Biopharma Inc. KNTE
2.65 +2.65
Day range unavailable
52-week range unavailable
News
businesswire.com KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate…
prnewswire.com Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. The transaction is in furtherance of…
globenewswire.com Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and…
zacks.com Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: What Does It Mean for the Stock? Kinnate Biopharma Inc. (KNTE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
businesswire.com KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate…
prnewswire.com ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc. NEW YORK , Feb. 16, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kinnate Biopharma Inc. (NASDAQ: KNTE) and its board of directors concerning the…
prnewswire.com Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA MILWAUKEE , Feb. 16, 2024 /PRNewswire/ -- Ademi LLP is investigating Kinnate (Nasdaq: KNTE) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA. Click…
businesswire.com KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Kinnate Biopharma Inc. (NASDAQ: KNTE) to XOMA Corporation is fair to Kinnate…
globenewswire.com Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced it has…
globenewswire.com Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates SAN FRANCISCO and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced…
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 369 companies hit new 52-week lows.
zacks.com Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%.
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023 - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
globenewswire.com Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring SAN FRANCISCO and SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced…- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 283 companies set new 52-week lows.
globenewswire.com Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences SAN FRANCISCO and SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will…
investorplace.com 7 Stocks With Promising Upside Potential for 100% Returns While your friendly financial advisor will probably never recommend these terribly risky enterprises, sometimes, you're just in the mood for stocks with 100% upside potential. And with these ideas,…
pennystocks.com 4 Penny Stocks To Buy According To Insiders This Quarter Insiders think these are penny stocks to buy based on recent filings but are they worth the risk? The post 4 Penny Stocks To Buy According To Insiders This Quarter appeared first on Penny Stocks to…
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 345 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 147 stocks made new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 149 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's session, 99 companies made new 52-week lows.
globenewswire.com Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that a clinical trial…
benzinga.com Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 497 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 36 companies set new 52-week lows.
globenewswire.com Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation…- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 325 companies set new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022 Upgrades
- benzinga.com Why Norwegian Cruise Line Shares Climbed By Around 12%; Here Are 66 Biggest Movers From Yesterday Gainers Pintec Technology Holdings Limited (NASDAQ: PT) shares jumped 216.2% to close at $0.9058 on Wednesday.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 517 companies set new 52-week lows.
zacks.com Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: Here's What You Should Know Kinnate Biopharma Inc. (KNTE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
benzinga.com 89 Biggest Movers From Friday Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
globenewswire.com Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences SAN FRANCISCO and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will…
globenewswire.com Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022 Preclinical data from a study of the Company's pan-RAF product candidate, KIN-2787, in combination with MEK inhibitor, also accepted for publication in the meeting proceedings Preclinical data from a…
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 524 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday morning, 66 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 209 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 105 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 88 companies set new 52-week lows.
- benzinga.com 52 Biggest Movers From Yesterday Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Before 10 am on Friday, 110 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 615 stocks hit new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday morning, 173 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday morning, 282 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the morning session on Thursday, 152 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's morning session, 88 stocks hit new 52-week lows.